TickerFacts.

BridgeBio Pharma, Inc. (BBIO): Long-Term Debt

Annual figures by period end, from SEC filings.

$2.01B
As of 2025-12-31
$2.65B
As of 2026-06-30
+84.5%
5-year compound annual growth
2019-12-31: $95.37M2020-12-31: $93.88M2025-12-31: $2.01B$2.01B
2019-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$2.01Bn/a2026-02-24, Balance as of period end
No annual figure between 2020-12-31 and 2025-12-31.
2020-12-31$93.88M-1.6%2022-02-25, Balance as of period end
2019-12-31$95.37Mn/a2020-03-03, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
BridgeBio Pharma, Inc. (BBIO)2025-12-31$2.01Bn/a
HUTCHMED (China) Ltd (HCM)2025-12-31$93.16M+12.5%
Insmed Inc (INSM)2025-12-31$546.77M-51.3%
Opko Health, Inc. (OPK)2025-12-31$343.97M-21.3%
Ardelyx, Inc. (ARDX)2025-12-31$202.83M+34.5%
Sinovac Biotech Ltd (SVA)2025-12-31$494.86M+31.7%
Arcutis Biotherapeutics, Inc. (ARQT)2025-12-31$108.96M+1.6%
MannKind Corp (MNKD)2025-12-31$354.64M+883.7%
Pacira BioSciences, Inc. (PCRX)2025-12-31$372.19M-36.4%

Compare BBIO, HCM, INSM, OPK side by side · Screen every company in Pharmaceutical Preparations ↗